Effect of Metoclopramide Versus Erythromycin on on Gastric Residual Volume

NCT ID: NCT04682691

Last Updated: 2025-01-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-01

Study Completion Date

2024-02-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In emergencies, it may be necessary to anaesthetize who are not fully starved and consequently at risk of pulmonary aspiration. Pregnancy are recognized to be at increased risk of aspiration compared with non-pregnancy. Prokinetic agents such as metoclopramide can be used to reduce GRV. Metoclopramide is widely used as a prokinetic agent in adults and is licensed for premedication in pregnancy, but its use may be limited by its potential for producing extrapyramidal side effects. Erythromycin is an effective prokinetic agent in adults but there is no work examining its use for premedication in pregnancy. This study compared the effects of erythromycin and metoclopramide on GRV in full-term pregnant women

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Residual Volume

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group (C)

will be receive flavored water in total volume 15 ml

Group Type SHAM_COMPARATOR

naturally flavored water

Intervention Type DIETARY_SUPPLEMENT

naturally flavored water

Group (M)

will be receive 10 ml of oral metoclopramide (10mg) + 5 ml of flavored water in total volume 15 ml

Group Type ACTIVE_COMPARATOR

metoclopramide (10mg)

Intervention Type DRUG

oral metoclopramide (10mg)

Group (E)

will be receive 10 ml of oral Erythromycin (400mg) + 5 ml of flavored water in total volume 15 ml

Group Type ACTIVE_COMPARATOR

Erythromycin (400mg)

Intervention Type DRUG

oral Erythromycin (400mg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Erythromycin (400mg)

oral Erythromycin (400mg)

Intervention Type DRUG

metoclopramide (10mg)

oral metoclopramide (10mg)

Intervention Type DRUG

naturally flavored water

naturally flavored water

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-laboring pregnant women ≥36 weeks gestational age
* Parturient scheduled for elective caesarian delivery.
* Singleton pregnancy
* Age greater than 18 years
* Having followed institutional fasting guidelines (a minimum of 2 h for clear fluids, 6 h for a light meal, and 8 h for a meal that included fried or fatty food)

Exclusion Criteria

* Refusal of the patient
* Deviation from fasting times
* Patients with empty stomach
* Emergency operation
* Body mass index (BMI) greater than 40 kg/m2
* American Society of Anesthesiologists (ASA) physical status class III, IV.
* Gestational diabetes mellitus
* Multiple gestations
* Patients with polyhydramnios liquor.
* Preeclampsia patients
* Chronic kidney disease patients
* Systemic diseases may cause delayed gastric emptying (eg: myopathies and myasthenia gravis).
* Patients with gastrointestinal diseases such as hiatus hernia, intestinal disease and gastro-oesophageal reflux disease and patients with history of upper gastrointestinal surgeries.
* Patients on antidepressants and monoamine oxidase inhibitors
* Use of other medications known to affect gastric motility or secretions.
* Allergy to macrolide or metoclopramide
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Amr Samir Wahdan

Lecturer of Anesthesia, Pain management and Surgical ICU

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amr wahdan, MD

Role: PRINCIPAL_INVESTIGATOR

Cairo university , Cairo, Egypt

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Medicine, Cairo University.

Cairo, Egypt, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MS-381-2020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.